Ceraxon, 10 pcs., 10 ml, 100 mg/ml, oral solution
Solution for intravenous, intramuscular administration.
IV, in the form of a slow IV injection (over 3–5 minutes, depending on the prescribed dose) or IV drip infusion (40–60 drops per minute).
The intravenous route of administration is preferable to the intramuscular route. When administered intramuscularly, repeated administration of the drug in the same place should be avoided.
Recommended dosage regimen
Acute period of ischemic stroke and TBI:
1000 mg every 12 hours from the first day after diagnosis, duration of treatment for at least 6 weeks. 3–5 days after the start of treatment (if swallowing function is not impaired), it is possible to switch to oral forms of the drug Ceraxon®.
Recovery period of ischemic and hemorrhagic strokes, recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain:
500–2000 mg per day. The dosage and duration of treatment depend on the severity of the symptoms of the disease. It is possible to use oral forms of the drug Ceraxon®.
Elderly patients
When prescribing Ceraxon® to elderly patients, no dose adjustment is required.
The solution in the ampoule is intended for single use. It must be used immediately after opening the ampoule.
The drug is compatible with all types of intravenous isotonic solutions and dextrose solutions.
Oral solution.
Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup). Take with meals or between meals.
Recommended dosage regimen
Acute period of ischemic stroke and TBI:
1000 mg (10 ml or 1 pack) every 12 hours. Treatment duration is at least 6 weeks.
Recovery period of ischemic and hemorrhagic strokes, recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain:
500–2000 mg per day (5–10 ml or 1 pack (1000 mg) 1–2 times a day). The dosage and duration of treatment depend on the severity of the symptoms of the disease.
Elderly patients
When prescribing Ceraxon® to elderly patients, no dose adjustment is required.
Instructions for using the dosing syringe (Fig. 1):
Picture 1.
1. Place the dosing syringe into the bottle (the syringe plunger is completely lowered) (Fig. 1 (1).
2. Carefully pull the plunger of the dosing syringe until the solution level is equal to the corresponding mark on the syringe (Fig. 1 (2).
3. Before taking, the required amount of solution can be diluted in 1/2 glass of water (120 ml) (Fig. 1 (3).
After each use, it is recommended to rinse the dosing syringe with water.
Recommendations for the use of Ceraxon® in sachets:
1. Separate one bag from another along the tear seam. Holding the bag vertically, carefully tear off its edge along the o (Fig. 2).
Figure 2.
2. The contents of the sachet can be drunk immediately after opening (Fig. 3) or before use can be diluted in 1/2 glass of water (120 ml) (Fig. 4).
Figure 3.
Figure 4.
Buy Ceraxon solution intravenously and intramuscularly 1000 mg 4 ml No. 5 in pharmacies
Oral solution in the form of a clear, colorless liquid with a characteristic strawberry odor. Indications : acute period of ischemic stroke (as part of complex therapy); — recovery period of ischemic and hemorrhagic strokes; — traumatic brain injury, acute (as part of complex therapy) and recovery period; — cognitive and behavioral disorders in degenerative and vascular diseases of the brain. Dosage regimen IV drug is administered as a slow injection (over 3-5 minutes, depending on the prescribed dose) or drip infusion (40-60 drops/min). The intravenous route of administration is preferable to the intramuscular route. When administered intramuscularly, repeated administration of the drug in the same place should be avoided. Acute period of ischemic stroke and traumatic brain injury: the recommended dose is 1000 mg every 12 hours from the first day after diagnosis; Duration of treatment is at least 6 weeks. 3-5 days after the start of treatment (if swallowing function is not impaired), it is possible to switch to oral forms of the drug Ceraxon®. Recovery period for ischemic and hemorrhagic strokes, recovery period for traumatic brain injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: the recommended dose is 500-2000 mg/day (5-10 ml 1-2 times/day). The dose and duration of treatment depend on the severity of the symptoms of the disease. Elderly patients do not require dose adjustment of Ceraxon® for intravenous or intramuscular administration. A solution for intravenous and intramuscular administration in an ampoule is intended for single use. After opening the ampoule, the solution should be used immediately. The drug is compatible with all types of intravenous isotonic solutions and dextrose solutions. Side effects Very rare (<1/10,000) (including individual cases): allergic reactions (rash, itching, anaphylactic shock), headache, dizziness, feeling of heat, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath , insomnia, agitation, loss of appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes. In some cases, Ceraxon® can stimulate the parasympathetic system and also cause a short-term change in blood pressure. If any of the side effects indicated in the instructions get worse, or any other side effects not listed in the instructions are noticed, you should inform your doctor. Contraindications for use : severe vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system); - children and adolescents under 18 years of age (due to the lack of sufficient clinical data); - hypersensitivity to the components of the drug. Use during pregnancy and lactation There is not enough clinical data on the use of citicoline during pregnancy. Although experimental studies on animals have not revealed any negative effects, during pregnancy the drug is prescribed only when the expected benefit of therapy for the mother outweighs the potential risk to the fetus. If it is necessary to use the drug during lactation, the issue of stopping breastfeeding should be decided, since there is no data on the excretion of citicoline in breast milk. Use in children Contraindicated in children and adolescents under 18 years of age. Use in elderly patients Elderly patients do not require dose adjustment of Ceraxon®. Special instructions Impact on the ability to drive vehicles and operate machinery During the treatment period, patients should be careful when performing potentially dangerous activities that require special attention and speed of psychomotor reactions (including driving a car and other vehicles, working with moving mechanisms, work of the dispatcher and operator). Overdose Due to the low toxicity of the drug, cases of overdose have not been described. Drug interactions Citicoline enhances the effects of levodopa. Ceraxon® should not be prescribed concomitantly with medications containing meclofenoxate. Conditions and periods of storage The drug should be stored out of the reach of children at a temperature not exceeding 30°C. Shelf life: 3 years. Conditions for dispensing from pharmacies The drug is dispensed with a prescription.
Ceraxon solution for oral administration 100 mg/ml pack 10 ml N10
Registration Certificate Holder
FERRER INTERNACIONAL (Spain)
Dosage form
Medicine - Ceraxon®
Description
Oral solution
in the form of a clear, colorless liquid with a characteristic strawberry odor.
1 pack (10 ml)
citicoline sodium 1045 mg, equivalent to citicoline 1000 mg
Excipients
: sorbitol - 2000 mg, glycerol - 500 mg, methyl parahydroxybenzoate - 14.5 mg, propyl parahydroxybenzoate - 2.5 mg, sodium citrate dihydrate - 60 mg, sodium saccharinate - 2 mg, strawberry flavor (strawberry essence 1487-S-Lucta) - 4.08 mg, potassium sorbate - 30 mg, citric acid solution 50% - up to pH 5.9-6.1, purified water - up to 10 ml.
10 ml - sachets of combined material (6) - cardboard packs. 10 ml - sachets of combined material (10) - cardboard packs.
Indications
- acute period of ischemic stroke (as part of complex therapy);
- recovery period of ischemic and hemorrhagic strokes;
- traumatic brain injury, acute (as part of complex therapy) and recovery period;
- cognitive and behavioral disorders in degenerative and vascular diseases of the brain.
Contraindications for use
- pronounced vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);
- children and adolescents under 18 years of age (due to the lack of sufficient clinical data);
- rare hereditary diseases associated with fructose intolerance;
- hypersensitivity to the components of the drug.
pharmachologic effect
Nootropic drug. Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action: it promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, preventing the excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis.
In the acute period of stroke, citicoline reduces the volume of brain tissue damage and improves cholinergic transmission.
In case of traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms; in addition, citicoline helps to reduce the duration of the recovery period.
In chronic cerebral hypoxia, citicoline is effective in the treatment of cognitive disorders such as memory impairment, lack of initiative, and difficulties in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia.
Ceraxon® is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.
Drug interactions
Citicoline enhances the effects of levodopa.
Ceraxon® should not be prescribed concomitantly with medications containing meclofenoxate.
Dosage regimen
The drug is taken with meals or between meals. Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup).
Acute period of ischemic stroke and traumatic brain injury:
The recommended dose is 1000 mg (10 ml or 1 sachet) every 12 hours. The duration of treatment is at least 6 weeks.
Recovery period of ischemic and hemorrhagic strokes, recovery period of traumatic brain injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain:
The recommended dose is 500-2000 mg/day (5-10 ml 1-2 times/day or 1 sachet (1000 mg) 1-2 times/day). The dose and duration of treatment depend on the severity of the symptoms of the disease.
Elderly patients
No dose adjustment of Ceraxon® is required.
Rules for using a dosage syringe
1. Place the dosing syringe into the bottle (the syringe plunger is completely lowered).
2. Carefully pull the plunger of the dosing syringe until the solution level is equal to the corresponding mark on the syringe.
3. Before taking, the required amount of solution can be diluted in 1/2 glass of water (120 ml).
After each use, it is recommended to rinse the dosing syringe with water.
Rules for using the drug in sachets
1. Holding the bag vertically, carefully tear off its edge along the o.
2.The contents of the sachet can be drunk immediately after opening or before use can be diluted in 1/2 glass of water (120 ml).
Overdose
Due to the low toxicity of the drug, cases of overdose have not been described.
Side effect
Very rare (<1/10,000) (including individual cases):
allergic reactions (rash, skin itching, anaphylactic shock), headache, dizziness, feeling of heat, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath, insomnia, agitation, loss of appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes . In some cases, Ceraxon® can stimulate the parasympathetic system and also cause a short-term change in blood pressure.
If any of the side effects indicated in the instructions get worse, or any other side effects not listed in the instructions are noticed, you should inform your doctor.
special instructions
In the solution for oral administration in the cold, a small amount of crystals may form due to temporary partial crystallization of the preservative.
With further storage under recommended conditions, the crystals dissolve within several months. The presence of crystals does not affect the quality of the drug. Impact on the ability to drive vehicles and operate machinery
During treatment, patients should be careful when performing potentially dangerous activities that require special attention and speed of psychomotor reactions (including driving a car and other vehicles, working with moving mechanisms, working as a dispatcher and operator).
Storage conditions
The drug should be stored out of the reach of children at a temperature not exceeding 30°C.
Best before date
Shelf life: 3 years.
Use during pregnancy and breastfeeding
Restrictions during pregnancy - With caution. Restrictions when breastfeeding - Contraindicated.
There is insufficient clinical data on the use of citicoline during pregnancy. Although experimental studies on animals have not revealed any negative effects, during pregnancy the drug is prescribed only when the expected benefit of therapy for the mother outweighs the potential risk to the fetus.
If it is necessary to use the drug during lactation, the issue of stopping breastfeeding should be decided, since there is no data on the excretion of citicoline in breast milk.
Use in elderly patients
Restrictions for elderly patients - No restrictions.
Elderly patients
No dose adjustment of Ceraxon® is required.
Use in children
Restrictions for children - Contraindicated. Contraindicated in children and adolescents under 18 years of age.
Terms of sale
The drug is available with a prescription.
Contacts for inquiries
TAKEDA (Japan)
Takeda Pharmaceuticals LLC
119048 Moscow, st. Usacheva, 2, building 1 Business, fl. 5 Tel. Fax E-mail
